Cardiovascular diseases account for about 31% of all deaths worldwide - Synlab

Cardiovascular diseases account for about 31% of all deaths worldwide

Published by Synlab on 08 May 2024
Banner Principal Imagem de fundo seção

Genetic testing contributes to early cardiovascular disease risk detection and more effective pharmacological treatments

Cardiovascular diseases are disorders that include coronary heart diseases, cerebrovascular diseases, rheumatic heart diseases, among others. Currently, they are one of the leading causes of death. According to the WHO, in 2016 an estimated 17.9 million people   died of cardiovascular diseases, accounting for 31% of all deaths worldwide.

 

Over the past 15 years, molecular genetic studies have shown that genetic variations are associated to inherited arrhythmogenic disorders, in particular, channelopathies. These are caused by the inadequate movement of ions through ion channels, leading to an alteration in cardiac action potential. Variants have been described for genes that encode for functional units of ion channels associated with patients without structural cardiac alterations.

 

Despite the proper diagnosis and use of pharmacotherapy, it is estimated that about 40-60% of patients suffering from cardiovascular diseases are unable to experience the expected effect of prescribed medication. There is substantial interpatient variability in the response to pharmacological treatment, frequently associated with genetics, that is, genotype may influence the metabolism and sensitivity of drugs to a given prescribed treatment.

 

Genetic tests have risen to prominence as an important diagnostic tool that helps detect cardiovascular diseases early and that allows new therapeutic strategies for treating individuals who can present risk for fatal cardiopathies.

 

In light of recent genomic medicine studies, SYNLAB has an entire category of tests geared towards genetic predisposition to cardiovascular disease, including:

SYNLAB also offers, in its portfolio, exclusive pharmacogenetic panels to patients suffering from cardiovascular diseases, divided as: FG Cardio Arrythmia, FG Cardio Hypertension, FG Cardio Vascular, and FG Cardio Complete.

 

About SYNLAB

SYNLAB offers a full range of medical laboratory services for practising doctors, clinics and the pharmaceutical industry. The SYNLAB Group is the uncontested leader on the European market for human medicine laboratory services.

Find out about the exams

 

FG CARDIO ARRHYTHMIA
FG CARDIO HYPERTENSION
FG CARDIO VASCULAR
FG CARDIO COMPLETE

Related Posts

21/05/2024

Everything You Need to Know About Celiac Disease

Celiac disease (CD) is a global condition affecting about 1%…

Continue reading Icon Next
14/05/2024

Food Allergy and Intolerance: Understanding the Differences

Feeding is the process by which organisms obtain and incorporate…

Continue reading Icon Next
08/05/2024

The diagnosis of the intolerances in the era of food awareness

The eliminating of foods that cause hypersensitivity provides a noticeable…

Continue reading Icon Next

Search our blog

We want to share our news with you!

Stay informed by subscribing to our Newsletter and receive exclusive updates on cutting-edge diagnostic medicine worldwide.

Thank you for signing up to our Newsletter!

This email is already registered!

An error occurred, please try later!

Contact us